Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Receivables: 2009-2025

Historic Receivables for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $22.1 million.

  • Lifecore Biomedical's Receivables rose 8.78% to $22.1 million in Q2 2025 from the same period last year, while for May 2025 it was $110.9 million, marking a year-over-year increase of 29.80%. This contributed to the annual value of $22.1 million for FY2025, which is 8.78% up from last year.
  • As of Q2 2025, Lifecore Biomedical's Receivables stood at $22.1 million, which was down 0.70% from $22.3 million recorded in Q1 2025.
  • Lifecore Biomedical's Receivables' 5-year high stood at $53.6 million during Q1 2022, with a 5-year trough of $20.0 million in Q3 2023.
  • Its 3-year average for Receivables is $26.5 million, with a median of $22.6 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first slumped by 55.34% in 2023, then surged by 63.73% in 2024.
  • Lifecore Biomedical's Receivables (Quarterly) stood at $40.1 million in 2021, then fell by 10.57% to $35.9 million in 2022, then plummeted by 37.72% to $22.3 million in 2023, then spiked by 63.73% to $36.6 million in 2024, then increased by 8.78% to $22.1 million in 2025.
  • Its Receivables was $22.1 million in Q2 2025, compared to $22.3 million in Q1 2025 and $36.6 million in Q4 2024.